Abstract
BackgroundHigh-dose systemic immunosuppression (ISP) is associated with poorer survival outcomes in cancer patients treated with immune checkpoint inhibitors (ICIs).1–3 However, the effect of ISP timing on survival is not well-studied....
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have